Patients from neighboring states show interest in procedure.

By Randy Tucker
Staff Writer

Kettering Medical Center is offering its patients a novel new procedure that allows surgeons to treat malignant tumors deep within the brain that were previously considered inoperable.

The minimally invasive NeuroBlate System from medical device maker Monteris Medical uses a laser-probe inserted into a small incision in the skull that heats and kills tumor cells located with an MRI machine.

“The procedure minimizes risk to the healthy surrounding brain tissues, thereby allowing patients to recover much faster than traditional surgeries,” said Dr. Phillip Porcelli, one of two doctors performing NeuroBlate surgeries at Kettering. “It really cuts down on the stress on the body and the brain itself. It really is changing the future of not only health care, but neurosurgery in general.”

Read More: http://www.daytondailynews.com/news/news/local/kettering-offers-new-treatment-for-brain-tumors/njzJy/

REDWOOD CITY, Calif., Jan. 29, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development (OOPD) has granted orphan drug designation to tarextumab (anti-Notch 2/3, OMP-59R5) for the treatment of both pancreatic cancer and small cell lung cancer.


Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=893587

CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial
​
Remedy Pharmaceuticals, a clinical stage pharmaceutical company focused on the development and commercialization of an innovative central nervous system drug, CIRARA™, announced today that the Company strengthened its leadership team with the appointment of Ann Tunstall as Vice President of Regulatory and Operational Affairs, and Alan Cutler as Vice President of Chemistry Manufacturing and Controls.

"We’re excited to have Ann and Alan join our executive team,” commented Sven Jacobson, CEO of Remedy Pharmaceuticals. “They bring a wealth of experience and tremendous knowledge, which we believe will be a great asset to the company as we move closer to initiating our Phase 3 trial targeting brain swelling following severe stroke. We also look forward to their contributions as we accelerate our clinical trial efforts in other CNS conditions where swelling is an important determinant of outcome such as spinal cord injury, traumatic brain injury and subarachnoid hemorrhage.”

Read More: http://www.reuters.com/article/ny-remedy-pharmaceutical-idUSnBw055226a+100+BSW20160105